Abeona Therapeutics Inc. (NASDAQ:ABEO) CFO Sells $148,908.46 in Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) CFO Joseph Walter Vazzano sold 25,411 shares of Abeona Therapeutics stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total value of $148,908.46. Following the sale, the chief financial officer directly owned 479,168 shares in the company, valued at approximately $2,807,924.48. This trade represents a 5.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Joseph Walter Vazzano also recently made the following trade(s):

• On Friday, June 6th, Joseph Walter Vazzano sold 17,795 shares of Abeona Therapeutics stock. The shares were sold at an average price of $6.76, for a total value of $120,294.20.

Abeona Therapeutics Price Performance

Abeona Therapeutics stock traded down $0.11 during mid-day trading on Friday, hitting $5.74. The company's stock had a trading volume of 774,254 shares, compared to its average volume of 701,588. Abeona Therapeutics Inc. has a twelve month low of $3.93 and a twelve month high of $7.32. The company has a quick ratio of 4.90, a current ratio of 4.90 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $293.64 million, a P/E ratio of -4.52 and a beta of 1.51. The stock's fifty day moving average price is $6.01 and its two-hundred day moving average price is $5.57.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.11. Research analysts forecast that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.

Hedge Funds Weigh In On Abeona Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Twinbeech Capital LP purchased a new position in Abeona Therapeutics during the 4th quarter worth approximately $58,000. Squarepoint Ops LLC purchased a new position in shares of Abeona Therapeutics during the 4th quarter valued at $67,000. Cannon Global Investment Management LLC purchased a new position in shares of Abeona Therapeutics during the 1st quarter valued at $67,000. Oxford Asset Management LLP purchased a new position in shares of Abeona Therapeutics during the 4th quarter valued at $118,000. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Abeona Therapeutics during the 4th quarter valued at $190,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Oppenheimer assumed coverage on Abeona Therapeutics in a report on Monday, June 2nd. They set an "outperform" rating and a $19.00 price target on the stock. Alliance Global Partners reiterated a "buy" rating on shares of Abeona Therapeutics in a research note on Thursday, May 15th. Stifel Nicolaus lowered their price objective on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. HC Wainwright raised their price objective on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, April 30th. Finally, Wall Street Zen lowered shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 15th. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $19.25.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.